IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Gruenberg, M.

Serial No:

08/700,565

Filed:

July 25, 1996

For:

AUTOLOGOUS IMMUNE CELL
THERAPY: CELL COMPOSITIONS,

METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE.

Art Unit:

1644

Examiner:

Schwadron, R.

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents Washington, D.C. 20231, on this date.

12/08/00

Date

H. Jenrings

RECEIVED

DEC 15 2026

TRANSMITTAL LETTER

TECH CENTER 1600/2900

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, cited reference and Form PTO-1449 (1 page) for filing in connection with the above-identified application. Because this Supplemental Information Disclosure Statement is filed after receipt of a First Office Action on the merits for the above-captioned application but before either a Final Office Action or Notice of Allowance in the above-referenced application, a fee for filing this statement is included herewith. However, should said fee be either missing or incorrect, the Commissioner is authorized to charge deposit account No. 50-1213, for the appropriate fee as stated below:

The Commissioner is hereby authorized to charge any fee, including any submitted herewith if the attached check(s) is in the wrong amount or otherwise improper or missing, that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,

HELLER, ENRMAN, WHITE & McAULIFFE LLP

By:

Stephane L. Seidman Registration No. 33,779

12/14/2000 CNGHYEN 00000085 08700565

01-FC+126

-180.00 OP

Attorney Docket No.: 24731-500B Address all correspondence to: Stephanie Seidman, Esq.

HELLER, EHRMAN, WHITE & McAULIFFE LLP

4250 Executive Square, Suite 700,

La Jolla, California 92037

Telephone:

(858) 450-8400 (858) 587-5360

Facsimile: (858) 587-536 E-MAIL: sseidman@hewm.com

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

GRUENBERG, M,

Serial No.:

08/700,565

Filed:

July 25, 1996

For:

AUTOLOGOUS IMMUNE CELL

THERAPY: CELL

COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN

DISEASE

Art Unit:

1644

Examiner:

Schwadron, R.

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an

Ý,

envelope addressed to:

Assistant Commissioner for Patents, Washington, D.C. 20231, on this date.

12/08/00 Date

DEC 15 2000:

**TECH CENTER 1600/2900** 

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH 37 C.F.R. § 1.97-1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Because this Supplemental Information Disclosure Statement is filed after receipt of a First Office Action on the merits for the above-captioned application, the filing fee of \$240 is enclosed. If no proper payment is enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (1 page) and a copy of the cited document are provided herewith in connection with the above-captioned application.

The documents listed on the Forms PTO-1449 and supplied herewith are in the English language. Hence, in accordance with the requirements of

RECEIVED

DEC 15 2000.

TECH CENTER 1600/2900

U.S.S.N. 08/700,565 GRUENBERG SUPPLEMENTAL IDS

37 C.F.R. §1.98, as amended effective Manager 1992, no further explanation of the listed items is necessary.

DEC 1 2 2000

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing reference and it be made of record in the file history of the above-captioned application.

Respectfully submitted,

HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:

Stephanie Seidman

Registration No( \$3,779

Attorney Docket No. 24731-500B

Address all correspondence to:
Stephanie L. Seidman, Esq.
HELLER, EHRMAN, WHITE & McAULIFFE LLP
4250 Executive Square,
La Jolla, California 92037
Telephone: (858) 450-8400

Facsimile: (858) 450-8400 Facsimile: (858) 587-5360 E-Mail: sseidman@hewm.com